ÂÜÀòÂÒÂ×

Andrew Cicchetto is a Scientist at Empirico Inc., with experience in non-viral gene therapy platform development and immunosuppressive RNA therapeutic lipid nanoparticle payloads. Prior to this, Andrew was a research scientist at Poseida Therapeutics, Inc. where Andrew explored DNA format variations and engineered mutant proteins. Andrew completed their PhD in Molecular and Medical Pharmacology at UCLA, focusing on post-transcriptional regulation of metabolic genes. Andrew has also worked in various research roles at the University of California, Davis and Stem Cell Partners LLC. Their educational background includes a Master of Arts in Stem Cell Research and a Bachelor of Science in Biomedical Sciences from California State University-Sacramento.